ArticleCureus2026
Evaluation of Direct Medical Costs Associated With High-Risk Febrile Neutropenia Among Cancer Patients in a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The onset of febrile neutropenia (FN) demands dose reduction and usually temporary halting of chemotherapy, which could then affect the outcome of cancer treatment. In this study, we wanted to quantify the drugs used in treating febrile neutropenic episodes, the costs incurred as a result, and the outcomes of these episodes. Methods The study was a prospective observational study. Patients of either sex, of any age, and diagnosed with high-risk FN following cancer chemotherapy and hospitalized during the period of study were included. A total of 46 patients with 50 episodes of FN were enrolled. Data were collected from the department database and daily clinical notes and were entered into a pre-designed proforma. The drugs prescribed were classified as antibiotics and supportive medications. The drug cost of each episode was then calculated. The data were analysed using descriptive statistics. Results The mean age of participants was 26.66 years, with a median length of hospital stay of 10 days. This provides an estimate of the drug-related costs. A total of Rs. 8,21,731 was spent on drugs for the management of 50 episodes, and the average cost of an episode was Rs. 16,434. Of the total cost, Rs. 7,00,300 (85.22%) was spent on antimicrobials. Conclusion Considering the complexities of medical decision-making and quality of care, the role of cost needs to play a major role in therapeutic options. There is a need to develop value-based policies to achieve the best clinical outcomes while accounting for cost-effectiveness and polypharmacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.